Invizyne announces appointment of Michael Heltzen as CEO

Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems to produce “commercially important molecules and chemicals for everyday life,” announced the appointment of Michael Heltzen as CEO and the recent hirings of additional executives for its leadership team. Prior to joining Invizyne, Mr. Heltzen served as the Executive Vice President for Strategy at Paragraf Ltd, Chief Executive Officer of Cardea Bio Inc., as well as Chief Executive Officer and Chairman of Nanosens Innovations Inc., prior to its merger with Cardea Bio, the company noted. “Michael Heltzen is a highly experienced technology entrepreneur with a track record of commercializing breakthrough companies with promising science and IP, making him a valuable addition to the Invizyne leadership team as the company prepares its launch as an independent public company,” said Christopher Marlett, CEO of MDB Capital Holdings (MDBH), which identifies itself as “the primary investor in the company since inception.” The companies noted: “In February 2024, Invizyne filed its IPO registration statement on Form S-1 with the U.S. Securities and Exchange Commission for the sale of its common stock in a firm commitment public offering. The offering will be for 4,300,000 shares of common stock at a price per share of $4.00, for gross proceeds of $17.2 million. Invizyne has applied to list its common shares on The Nasdaq Stock Market under the ticker symbol ‘IZTC.’ As a MDB “Big Idea” Company, the broker dealer subsidiary of MDB intends to give preference to holders of MDB Class A Shares, after which it will give preference to the other beneficial shareholders of MDB. To the extent these foregoing groups do not purchase all the offered shares, then shares will be sold to other persons giving an indication for purchase of shares through their respective brokers or dealers. A registration statement relating to these securities has been filed with the SEC but has not yet become effective.”